HeartSciences (HSCS) Stock Price, News & Analysis

Company Overview

HeartSciences, Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

Key Stats

• Today's Range: $1.98 to $2.40
• 50-Day Range: $1.67 to $2.99
• 52-Week Range: $1.63 to $3.93
• Volume: 40,706 shs
• Average Volume: 47,229 shs
• Market Capitalization: $8.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

HeartSciences Stock Analysis - MarketRank™

HeartSciences scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

HeartSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

HeartSciences has a consensus price target of $8.00, representing about 267.0% upside from its current price of $2.18.

Amount of Analyst Coverage

HeartSciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartSciences are expected to grow in the coming year, from ($3.04) to ($2.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HeartSciences is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HeartSciences is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HeartSciences has a P/B Ratio of 31.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.56% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 1.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently decreased by 37.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartSciences does not currently pay a dividend.

Dividend Growth

HeartSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.39

News Sentiment

HeartSciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for HeartSciences this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for HSCS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HeartSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.90% of the stock of HeartSciences is held by insiders.

Percentage Held by Institutions

17.24% of the stock of HeartSciences is held by institutions.

Company Calendar

• Last Earnings: 7/23/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 9/10/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:HSCS
• CIK: 1468492
• Web: heartsciences.com
• Phone: 682-237-7781
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HeartSciences: $8.00
• High Price Target: $8.00
• Low Price Target: $8.00
• Potential Upside/Downside: +267.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.14 million
• Net Margins: N/A
• Pretax Margin: -211,669.36%
• Return on Equity: -358.60%
• Return on Assets: -144.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.53
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 31.14

Miscellaneous

• Outstanding Shares: 3,900,000
• Free Float: 3,708,000
• Market Cap: $8.50 million
• Optionable: Not Optionable
• Beta: 1.78